🇺🇸 FDA
Pipeline program

ADI-PEG-20, Troriluzole, AZD1390

GCAR-7213

Phase 3 small_molecule active

Quick answer

ADI-PEG-20, Troriluzole, AZD1390 for Oncology - Glioblastoma (GBM) is a Phase 3 program (small_molecule) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Adaptive Biotechnologies Corp
Indication
Oncology - Glioblastoma (GBM)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials